

---

## Disclosure of Value Transfers

---

### Methodological Note

<b>Country</b>	Serbia
<b>Entity Name</b>	Fresenius-Kabi doo Beograd
<b>Legal Basis for Disclosure</b>	Medicines for Europe Code of Conduct 2020, published February 2021
<b>Reporting Period</b>	2021
<b>Currency of disclosed values</b>	All values are disclosed in <input checked="" type="checkbox"/> EUR <input type="checkbox"/> [local currency, if required]
<b>Scope of disclosure</b>	The disclosure covers all interactions with HCPs related to prescription-only medicines for human use
<b>Value identification and Recognition</b>	All values disclosed are based on value transfers actually made the respective category that such value transfer has been made to a specific recipient as booked in the respective reporting period.
<b>Multi-Year Contracts</b>	Value transfers under multiyear contracts are part of the disclosed data to the extent that actual value transfers have been made in the respective reporting period.
<b>Data disclosed for</b>	All values are disclosed for <input type="checkbox"/> Recipients which have been engaged by entity <input checked="" type="checkbox"/> Recipients who have their residence in the country (e.g., EFPIA and Medicines for Europe)
<b>VAT and other taxes</b>	All amounts are disclosed include VAT or similar service taxes, where such apply on the transaction
<b>Disclosure location:</b>	<a href="http://www.fresenius-kabi.com/documents/Disclosure-2021-Serbia.pdf">www.fresenius-kabi.com/documents/Disclosure-2021-Serbia.pdf</a>

---

**Disclosure of Value Transfers**

---

<b>Other Remarks</b>	For value categories related to HCPs, aggregate values have been disclosed where the consent of a multiple number of HCP could not be obtained.  Fees paid in connection with research & development activities or market research have not been disclosed.
----------------------	---